Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis

Kenneth G. Saag; Tobias J. de Villiers; Peter Alexandersen; Heidi Jacobe; Carrie Kovarik; Victoria P. Werth; Albert Leung; Avani Desai-Merchant; Julie Mattaliano; Deborah Gurner

doi:10.1016/j.jaad.2020.06.036

Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis

Kenneth G. Saag, Tobias J. de Villiers, Peter Alexandersen, Heidi Jacobe, Carrie Kovarik, Victoria P. Werth, Albert Leung, Avani Desai-Merchant, Julie Mattaliano, Deborah Gurner

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1113-1119
Number of pages	7
Journal	Journal of the American Academy of Dermatology
Volume	84
Issue number	4
DOIs	https://doi.org/10.1016/j.jaad.2020.06.036
State	Published - Apr 2021

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2020.06.036

Cite this

Saag, K. G., de Villiers, T. J., Alexandersen, P., Jacobe, H., Kovarik, C., Werth, V. P., Leung, A., Desai-Merchant, A., Mattaliano, J., & Gurner, D. (2021). Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis. Journal of the American Academy of Dermatology, 84(4), 1113-1119. https://doi.org/10.1016/j.jaad.2020.06.036

Saag, KG, de Villiers, TJ, Alexandersen, P, Jacobe, H, Kovarik, C, Werth, VP, Leung, A, Desai-Merchant, A, Mattaliano, J & Gurner, D 2021, 'Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis', Journal of the American Academy of Dermatology, vol. 84, no. 4, pp. 1113-1119. https://doi.org/10.1016/j.jaad.2020.06.036

@article{fd2b75f8ac0943c48e8c2cf407392ada,

title = "Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis",

author = "Saag, {Kenneth G.} and {de Villiers}, {Tobias J.} and Peter Alexandersen and Heidi Jacobe and Carrie Kovarik and Werth, {Victoria P.} and Albert Leung and Avani Desai-Merchant and Julie Mattaliano and Deborah Gurner",

note = "Funding Information: Disclosure: Dr Saag has received research grants from Amgen , Mereo , Merck Sharp & Dohme Corp. (MSD), and Radius , and consulting fees from Amgen, MSD, Radius, and Roche. Dr de Villiers has received consulting/speaker fees from Abbott, Amgen, Aspen, Adcock Ingram, MSD, and Pfizer. Drs Jacobe, Kovarik, and Werth have received consulting fees from MSD. Dr Leung, Authors Desai-Merchant and Julie Mattaliano, and Dr Deborah Gurner are current or former employees of MSD, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, and may own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, New Jersey. Funding Information: Funding sources: Funding for this research and medical writing assistance was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. , Kenilworth, New Jersey, USA. ",

year = "2021",

month = apr,

doi = "10.1016/j.jaad.2020.06.036",

language = "English (US)",

volume = "84",

pages = "1113--1119",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "4",

}

TY - JOUR

T1 - Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis

AU - Saag, Kenneth G.

AU - de Villiers, Tobias J.

AU - Alexandersen, Peter

AU - Jacobe, Heidi

AU - Kovarik, Carrie

AU - Werth, Victoria P.

AU - Leung, Albert

AU - Desai-Merchant, Avani

AU - Mattaliano, Julie

AU - Gurner, Deborah

N1 - Funding Information: Disclosure: Dr Saag has received research grants from Amgen , Mereo , Merck Sharp & Dohme Corp. (MSD), and Radius , and consulting fees from Amgen, MSD, Radius, and Roche. Dr de Villiers has received consulting/speaker fees from Abbott, Amgen, Aspen, Adcock Ingram, MSD, and Pfizer. Drs Jacobe, Kovarik, and Werth have received consulting fees from MSD. Dr Leung, Authors Desai-Merchant and Julie Mattaliano, and Dr Deborah Gurner are current or former employees of MSD, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, and may own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, New Jersey. Funding Information: Funding sources: Funding for this research and medical writing assistance was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. , Kenilworth, New Jersey, USA.

PY - 2021/4

Y1 - 2021/4

UR - http://www.scopus.com/inward/record.url?scp=85101124703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101124703&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2020.06.036

DO - 10.1016/j.jaad.2020.06.036

M3 - Article

C2 - 32553680

AN - SCOPUS:85101124703

SN - 0190-9622

VL - 84

SP - 1113

EP - 1119

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 4

ER -

Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this